Cough, being a public manifestation of a wide range of diseases, significantly reduces the quality of life of patients and remains the most common reason for seeking medical help in outpatient practice. The classification of cough traditionally involves dividing it into acute, subacute and chronic. According to the results of the studies, more than half of patient complaints are related to the acute and subacute cough, which in most cases has infectious origin. In the clinical picture of respiratory infections, cough is often the most painful and long-lasting symptom. Treatment of cough, first of all, involves eliminating its causes. At the same time, there is a need for the use of symptomatic therapy. The basis of symptomatic therapy includes mucoactive drugs, the clinical effect of which is characterized by facilitating sputum discharge and reducing the intensity of cough. Among the drugs used in this clinical situation, an important place is occupied by combined mucoactive drugs, which have a complex effect and ensure maximum effectiveness of treatment. This article examines modern views on the symptomatic treatment of cough and discusses the possibility of using a combined domestic drug containing bromhexine, guaifenesin and salbutamol (Bromgecomb®) in patients in this category.

Keywords: Bromgecomb®, guaifenesin, bromhexine, salbutamol, mucoactive drugs, acute bronchitis, cough